Evidence map›Paper›PMID 25295115›Full record

ArticleOncology letters2014

Alternating expression levels of

Elżbieta Płuciennik, Magdalena Nowakowska, Anna Stępien, Mateusz Wołkowicz, Adam Stawiński, Waldemar Różański, Marek Lipiński, Andrzej K Bednarek

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Fragile GeneFrontiers in oncology · 2021
    Article
  5. TheExperimental biology and medicine (Maywood, N.J.) · 2020
    Review
  6. TheFrontiers in cellular neuroscience · 2019
    Article
  7. BcCluster: A Bladder Cancer Database at the Molecular Level.Bladder cancer (Amsterdam, Netherlands) · 2016
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Elżbieta PłuciennikDepartment of Molecular Cancerogenesis, Medical University of Lodz, Lodz 90-752, Poland.
Magdalena NowakowskaDepartment of Molecular Cancerogenesis, Medical University of Lodz, Lodz 90-752, Poland.
Anna StępienLaboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital in Lodz, Lodz 93-513, Poland.
Mateusz WołkowiczBio-Tech Consulting Ltd., Lodz 90-212, Poland.
Adam StawińskiDepartment of Molecular Cancerogenesis, Medical University of Lodz, Lodz 90-752, Poland.
Waldemar RóżańskiSecond Department of Urology, Medical University of Lodz, Copernicus Memorial Hospital in Lodz, Lodz 93-513, Poland.
Marek LipińskiSecond Department of Urology, Medical University of Lodz, Copernicus Memorial Hospital in Lodz, Lodz 93-513, Poland.
Andrzej K BednarekDepartment of Molecular Cancerogenesis, Medical University of Lodz, Lodz 90-752, Poland.
Medical University of Lodz · PLCopernicus Memorial Hospital · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to determine the roles of the

Indexed as

bladder cancerloss of heterozygositymethylationreverse transcription-quantitative polymerase chain reactionWWOX tumor suppressor

Identifiers

PMID25295115
PMCPMC4186597
OpenAlexW1992821691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.